Ibalizumab，研发名称为「TMB-355」（最早称为「TNX-355」），是一种非免疫单株抗体，它会跟人类免疫缺陷病毒的主要受体——CD4受体结合，并克制病毒感染细胞的过程。这个药剂最早是由何大一教授指导下，于艾伦·戴蒙德爱滋病研究中心（Aaron Diamond AIDS Research Center）所发展出来。因为它具备阻挡具有CCR5受体与CXCR4受体的病毒进入细胞的能力，科学家目前正在研究能否将它当成爱滋病进入抑制剂（Entry inhibitor）。

Tanox公司在2006年完成第二期临床实验，在统计上，此药物优于安慰剂，显示它具备某种程度的疗效。目前这个药剂正由**的中裕新药公司（旧名宇昌生技）研发中。

Ibalizumab (TMB-355 previously known as TNX-355) is a non-immunosuppressive monoclonal antibody that binds CD4, the primary receptor for HIV, and inhibits the viral entry process. It is being investigated as an HIV entry inhibitor with the ability to block both CCR5- and CXCR4-tropic viruses, and is undergoing a Phase II clinical trial with an estimated study completion date in December 2010. Specific Research is also conducted at the Aaron Diamond AIDS Research Center under the direction of David Ho.